ARCH Venture Partners

ARCH Venture Partners

A venture capital firm in Illinois that focuses on life science discoveries to prevent, detect and cure disease.

All edits

Edits on 27 June, 2020
Golden AI
Golden AI edited on 27 June, 2020 12:45 am
Edits made to:
Infobox (+1 properties)
Infobox
Invested in
Edits on 3 April, 2020
Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 3 April, 2020 6:36 am
Edits made to:
Article (+13/-13 characters)
Article

ARCH Venture Partners is a venture capital firm in Illinois that focuses on life science discoveries to prevent, detect and cure disease. Founded 1986 in Chicago, Illinois, United StatesUnited States by Clinton Bybee, Keith Crandell, Robert Nelsen and Steven Lazarus, it invests in early stage ventures, seed, series B, series A, series C, and post-IPO equity. Its portfolio companies include Volastra Therapeutics, Sonoma BioTherapeutics, Vizgen, EQRx, and Omniome. As of April 2020, ARCH Venture Partners has made 321 investments. Their most recent investment was on February 11, 2020, when Volastra Therapeutics raised $12M. ARCH Venture Partners has had 69 exits, the most notable of which include Twist Bioscience, Alnylam Pharmaceuticals, and Juno Therapeutics. The company has raised 10 funds, their latest being ARCH Venture Fund X. This fund was announced on October 25, 2019 and raised a total of $635.8M.

Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 3 April, 2020 6:08 am
Edits made to:
Article (+23/-23 characters)
Article

ARCH Venture Partners is a venture capital firm in Illinois that focuses on life science discoveries to prevent, detect and cure disease. Founded 1986 in Chicago, Illinois, United States by Clinton Bybee, Keith Crandell, Robert Nelsen and Steven Lazarus, it invests in early stage ventures, seed, series B, series A, series C, and post-IPO equity. Its portfolio companies include Volastra Therapeutics, Sonoma BioTherapeutics, Vizgen, EQRx, and Omniome. As of April 2020, ARCH Venture Partners has made 321 investments. Their most recent investment was on February 11, 2020, when Volastra Therapeutics raised $12M. ARCH Venture Partners has had 69 exits, the most notable of which include Twist Bioscience, Alnylam PharmaceuticalsAlnylam Pharmaceuticals, and Juno Therapeutics. The company has raised 10 funds, their latest being ARCH Venture Fund X. This fund was announced on October 25, 2019 and raised a total of $635.8M.

Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 3 April, 2020 4:58 am
Edits made to:
Article (+16/-16 characters)
Article

ARCH Venture Partners is a venture capital firm in Illinois that focuses on life science discoveries to prevent, detect and cure disease. Founded 1986 in Chicago, Illinois, United States by Clinton Bybee, Keith Crandell, Robert Nelsen and Steven Lazarus, it invests in early stage ventures, seed, series B, series A, series C, and post-IPO equity. Its portfolio companies include Volastra Therapeutics, Sonoma BioTherapeutics, Vizgen, EQRx, and Omniome. As of April 2020, ARCH Venture Partners has made 321 investments. Their most recent investment was on February 11, 2020, when Volastra Therapeutics raised $12M. ARCH Venture Partners has had 69 exits, the most notable of which include Twist BioscienceTwist Bioscience, Alnylam Pharmaceuticals, and Juno Therapeutics. The company has raised 10 funds, their latest being ARCH Venture Fund X. This fund was announced on October 25, 2019 and raised a total of $635.8M.

Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 3 April, 2020 4:20 am
Edits made to:
Article (+17/-17 characters)
Article

ARCH Venture Partners is a venture capital firm in Illinois that focuses on life science discoveries to prevent, detect and cure disease. Founded 1986 in Chicago, Illinois, United States by Clinton Bybee, Keith Crandell, Robert Nelsen and Steven Lazarus, it invests in early stage ventures, seed, series B, series A, series C, and post-IPO equity. Its portfolio companies include Volastra Therapeutics, Sonoma BioTherapeutics, Vizgen, EQRx, and Omniome. As of April 2020, ARCH Venture Partners has made 321 investments. Their most recent investment was on February 11, 2020, when Volastra Therapeutics raised $12M. ARCH Venture Partners has had 69 exits, the most notable of which include Twist Bioscience, Alnylam Pharmaceuticals, and Juno TherapeuticsJuno Therapeutics. The company has raised 10 funds, their latest being ARCH Venture Fund X. This fund was announced on October 25, 2019 and raised a total of $635.8M.

Edits on 2 April, 2020
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 2 April, 2020 11:14 am
Edits made to:
Article (+4/-4 characters)
Article

ARCH Venture Partners is a venture capital firm in Illinois that focuses on life science discoveries to prevent, detect and cure disease. Founded 1986 in Chicago, Illinois, United States by Clinton Bybee, Keith Crandell, Robert Nelsen and Steven Lazarus, it invests in early stage ventures, seed, series B, series A, series C, and post-IPO equity. Its portfolio companies include Volastra Therapeutics, Sonoma BioTherapeutics, Vizgen, EQRxEQRx, and Omniome. As of April 2020, ARCH Venture Partners has made 321 investments. Their most recent investment was on February 11, 2020, when Volastra Therapeutics raised $12M. ARCH Venture Partners has had 69 exits, the most notable of which include Twist Bioscience, Alnylam Pharmaceuticals, and Juno Therapeutics. The company has raised 10 funds, their latest being ARCH Venture Fund X. This fund was announced on October 25, 2019 and raised a total of $635.8M.

Marie Gabrielle Laguna-Bedia
Marie Gabrielle Laguna-Bedia edited on 2 April, 2020 11:08 am
Edits made to:
Infobox (+2/--1 properties)
Timeline (+1 events) (+7 characters)
Description (+113/-150 characters)
Article (+902 characters)
Companies (+7 rows) (+7 cells) (+81 characters)
Topic thumbnail

ARCH Venture Partners

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

A venture capital firm in Illinois that focuses on life science discoveries to prevent, detect and cure disease.

Article

ARCH Venture Partners is a venture capital firm in Illinois that focuses on life science discoveries to prevent, detect and cure disease. Founded 1986 in Chicago, Illinois, United States by Clinton Bybee, Keith Crandell, Robert Nelsen and Steven Lazarus, it invests in early stage ventures, seed, series B, series A, series C, and post-IPO equity. Its portfolio companies include Volastra Therapeutics, Sonoma BioTherapeutics, Vizgen, EQRx, and Omniome. As of April 2020, ARCH Venture Partners has made 321 investments. Their most recent investment was on February 11, 2020, when Volastra Therapeutics raised $12M. ARCH Venture Partners has had 69 exits, the most notable of which include Twist Bioscience, Alnylam Pharmaceuticals, and Juno Therapeutics. The company has raised 10 funds, their latest being ARCH Venture Fund X. This fund was announced on October 25, 2019 and raised a total of $635.8M.

Companies

Company
CEO
Location
Products/Services

Epirium Bio

EQRx

Omniome

Sonoma BioTherapeutics

Transcenta

Vizgen

Volastra Therapeutics

Infobox
Company status
Active
Founded date
1986
Invested in
Timeline

1986

Founded

Edits on 5 August, 2019
Neelam Jhaveri
Neelam Jhaveri edited on 5 August, 2019 6:38 am
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 31 July, 2019
Golden AI"IBI-76"
Golden AI edited on 31 July, 2019 11:59 pm
Edits made to:
Infobox (+1 properties)
Infobox
Location
Edits on 30 May, 2019
Golden AI
Golden AI edited on 30 May, 2019 11:54 pm
Edits made to:
Infobox (+1 properties)
Infobox
Associated investment funds
Golden AI
Golden AI edited on 30 May, 2019 11:54 pm
Edits made to:
Infobox (+1 properties)
Infobox
Associated investment funds
Golden AI
Golden AI edited on 30 May, 2019 11:54 pm
Edits made to:
Infobox (+1 properties)
Infobox
Associated investment funds
Golden AI
Golden AI edited on 30 May, 2019 11:54 pm
Edits made to:
Infobox (+1 properties)
Infobox
Associated investment funds
Golden AI
Golden AI edited on 30 May, 2019 11:54 pm
Edits made to:
Infobox (+1 properties)
Infobox
Associated investment funds
Golden AI
Golden AI edited on 30 May, 2019 11:54 pm
Edits made to:
Infobox (+1 properties)
Infobox
Associated investment funds
Edits on 29 May, 2019
Jed Christiansen
Jed Christiansen edited on 29 May, 2019 6:06 pm
Edits made to:
Infobox (+3 properties)
Description (+150/-48 characters)
Topic thumbnail

ARCH Venture Partners

Early stage venture capital for technology firms

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Infobox
Edits on 12 February, 2019
Golden AI"Import data"
Golden AI edited on 12 February, 2019 12:38 am
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 11 February, 2019
Baye Maniago
Baye Maniago approved a suggestion from Golden's AI on 11 February, 2019 4:39 am
Edits made to:
Infobox (+6 properties)
People (+6 rows) (+12 cells) (+118 characters)
People

Name
Role
Related Golden topics

Amber Lu

Employee

Joshua White

Advisor

Keith Gillard

Board member

Michael Knapp

Employee

Mike Slawson

Employee

Vu Nguyen

Investor

Infobox
Edits on 29 May, 2018
Tianchang He
Tianchang He edited on 29 May, 2018 11:04 pm
Edits made to:
Description (+48/-21 characters)
Categories (-1 topics)
Topic thumbnail

ARCH Venture Partners

Biotechnology company

Early stage venture capital for technology firms

Categories
Edits on 29 May, 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 29 May, 2018 9:45 pm
Edits made to:
Description (+21 characters)
Categories (+1 topics)
Topic thumbnail

 ARCH Venture Partners

Biotechnology company

Categories
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.